Vertex Pharmaceuticals Incorporated today announced data from a Phase 4 study of JOURNAVX® (suzetrigine), a prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results